In September 2020, eight ministries and commissions of China, including the State Administration for Market Regulation and the National Medical Products Administration, jointly issued the Work Plan for Supervision, Innovation and Development of Drugs and Medical Devices in Guangdong-Hong Kong-Macao Greater Bay Area. The Work Plan specifies HKU-SZH as the only medical institution for the pilot introduction of drugs and medical devices in urgent clinical use that have been listed in Hong Kong and Macao but have not been approved for registration by the National Medical Products Administration (NMPA) and cannot be replaced by registered varieties in the Chinese mainland. To implement the measure efficiently, the Hospital has set up a cross-border drugs and medical devices team headed by Hospital Chief Executive, established a full-process management system and work flow, assigned special storage and observation rooms, and developed a Wechat mini-program for the use of drugs. Procedures are required to be controlled and supervised with the lowest risks and implemented steadily with substantial results.

As of December 2021, thirteen drugs and three medical devices had been approved under the measure. They have been put into clinical use, bringing tangible benefits for patients.